Clinical trials: Luminal Breast Cancer
Breast Cancer Female, Lobular Breast Carcinoma
18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer
Study hypothesis is that combining the advantages of hybrid PET/MRI and the high sensitivity/specificity of 16-alpha-18F-fluoro-17-beta-estradiol(FES), a radiolabeled form of estrogen binding to functionally active ER, the…
- Conditions
- Breast Cancer Female, Lobular Breast Carcinoma, PET/MRI, Axillary Lymphadenopathy
- Trial name
- FESTA (NCT05982496)
- Testing
- FES, PET/MRI A, Translational analysis
- Where
- Italy
- Volunteers
- 119 people
- Sponsor
- Università Vita-Salute San Raffaele
Hormone Dependent Neoplasms, Breast Cancer Female
HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer
Breast Cancer is a public health issue worldwide. The time from diagnosis to treatment initiation varies from country to country and regionally within a country.
- Trial name
- HOTBreast (NCT03111615)
- Testing
- Aromatase Inhibitors
- Where
- Portugal
- Volunteers
- 90 people
- Sponsor
- Centro Hospitalar Lisboa Ocidental
Breast Neoplasms
Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.
The aim of this prospective, randomized, multicenter, open-label, phase II study is to test if chemotherapy can be replaced by the combination of ribociclib plus letrozole as a neo-adjuvant therapy for patients with…
- Trial name
- NEOLBC (NCT03283384)
- Testing
- Letrozole, Chemotherapy, Ribociclib plus letrozole
- Where
- 29 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- Borstkanker Onderzoek Groep
Breast Cancer, Radiotherapy
Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast Cancer
IBISCO TRIAL is a phase II trial aimed to demonstrate the improvement of pathological complete response (pCR) in Luminal B breast cancer (BC) patients treated with stereotactic radiation therapy (SBRT) as an anticipated boost…
- Trial name
- NCT05673304
- Testing
- SBRT anticipated boost
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Cancer, Advanced Breast Cancer
Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
This is a randomized, controlled, open-label, phase II study to explore the efficacy and safety of Everolimus in combination with standard first-line endocrine therapy for the HR+/ HER2-SNF1 subtype of advanced breast cancer.
- Trial name
- BCTOP-L-M01 (NCT05949541)
- Testing
- Everolimus 10 mg, CDK4/6 Inhibitor SHR6390, Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Fudan University
Breast Cancer, Triple Negative Breast Cancer
Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)
This is a single centre Window-of-Opportunity trial investigating the efficacy and feasibility of short term imatinib in patients with newly diagnosed triple negative breast cancer (TNBC) planned for surgery, with tumours ≥ 15…
- Trial name
- I-CONIC (NCT05722795)
- Testing
- Imatinib 400 MG Oral Tablet
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Vastra Gotaland Region
Breast Neoplasms
Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer
RATIONALE: Estrogen can promote proliferation of tumor cells in hormone receptors (HR)-positive breast cancer. The standard therapy of Luminal subtypes is endocrine therapy, which can influence proliferation of tumor cells by…
- Trial name
- NCT04023292
- Testing
- Endocrine therapy
- Where
- China
- Volunteers
- 185 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
The purpose of the study is to determine the diagnostic role of ctDNA when used to monitor metastatic breast cancer (MBC) during first-line endocrine therapy.
- Conditions
- Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms, Neoplasms, Breast, Breast Diseases
- Trial name
- MAGNETIC1 (NCT05814224)
- Testing
- Liquid biopsy and CT scan
- Where
- 7 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Breast Carcinoma, Metastatic Breast Cancer
Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for newly Diagnosed Breast Carcinoma patients with distant metastases
- Conditions
- Breast Carcinoma, Metastatic Breast Cancer, Invasive Breast Cancer, Distant Metastases.Pathology
- Trial name
- NCT03970967
- Testing
- Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Russia
- Volunteers
- 1 people
- Sponsor
- Alpha Tau Medical LTD.
Neoadjuvant Operable Breast Cancer
Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women
The investigators propose in the present study an innovative approach, combining the most recent therapeutic opportunities in high risk ER+ breast cancer with the most recent and innovative diagnostic approaches such as the PAM50…
- Trial name
- NeoPAL (NCT02400567)
- Testing
- Fluorouracile, Epirubicin, Cyclophosphamide
- Where
- 2 sites in France
- Volunteers
- 125 people
- Sponsor
- UNICANCER
Metastatic Breast Cancer
CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer
This study is a retrospective review aimed at evaluating the real-world outcomes and clinical efficacy of CDK4/6 inhibitors (such as Palbociclib, Ribociclib, or Abemaciclib) in patients diagnosed with metastatic luminal A and…
- Trial name
- OCDMBC (NCT07704801)
- Testing
- CDK4/6 inhibitors
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- Sohag University
Metastatic Solid Tumor, Advanced Cancer
High Definition Medicine for Solid Tumors Oncology
The present study aims to analyze different genetic, phenotypic, environmental, social and lifestyle characteristics of cancer patients who are going to start a first line of cancer treatment with palliative intent and their…
- Trial name
- HDM-PMP22 (NCT06590506)
- Testing
- Wearable
- Where
- 9 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Breast Cancer, Breast Cancer Metastatic
Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)
This study evalues the efficacy -as determined by the clinical benefit rate (CBR)- of niraparib in combination with AIs in unresectable locally advanced or metastatic HR-positive/HER2-negative breast cancer patients harboring…
- Trial name
- LUZERN (NCT04240106)
- Testing
- Niraparib, Aromatase Inhibitors
- Where
- 10 sites in Spain
- Volunteers
- 14 people
- Sponsor
- MedSIR
Breast Cancer, Recurrence
RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast Cancer
This study will conduct a multicenter, open, prospective clinical trial to observe the RecurIndex to assist in predicting the risk of recurrence in patients with early-stage Luminal-type breast cancer.
- Trial name
- NCT04972448
- Volunteers
- 500 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer Female
Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer
Patient derived xenografts (PDX) from mammary tumors are usually made from metastatic tumors. Indeed, PDX from primitive mammary tumors or after neoadjuvant treatment are still rare.
- Trial name
- XenoBreast (NCT04133077)
- Testing
- blood samples collection
- Where
- France
- Volunteers
- 85 people
- Sponsor
- Centre Jean Perrin
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
ON-treatment Single-cell Analysis for the Identification of Early Tumor Response Biomarkers on Prospective Collected Serial Tumor Biopsies in Triple Negative Breast Cancer Patient During Standard Neoadjuvant Chemo-immunotherapy
This study explores early breast cancer, focusing on triple-negative and high-risk luminal subtypes. It combines single-cell RNA sequencing and spatial imaging of tumor samples collected at different time points during treatment.
- Trial name
- ONSET (NCT07597642)
- Testing
- on treatment biopsy (after C1)
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- IRCCS San Raffaele
Luminal B/HER2-negative Breast Cancer
Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)
Evaluate the efficacy and safety of Dalpiciclib combined with aromatase inhibitors as a neoadjuvant therapy in Luminal B/HER2-negative breast cancer.
- Trial name
- NCT05640778
- Testing
- Dalpiciclib combined with aromatase inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer, HER2-negative Breast Cancer
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
PREMIERE parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter, exploratory window of opportunity study in premenopausal women with primary operable HR+/HER2-negative breast cancer with aiming at evaluating…
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Premenopausal Breast Cancer
- Trial name
- SOLTI-2104 (NCT05982093)
- Testing
- Elacestrant, Triptorelin, Tamoxifen 20 mg
- Where
- 15 sites in Spain
- Volunteers
- 96 people
- Sponsor
- SOLTI Breast Cancer Research Group
Breast Cancer
Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer
The primary objective of this study is to compare progression-free survival (PFS) of patients with metastatic Luminal B2 breast cancer subtype randomised to treatment with Trastuzumab Combined With Chemotherapy or Endocrine…
- Trial name
- SYSUCC-002 (NCT01950182)
- Testing
- Endocrine therapy combined with trastuzumab, Chemotherapy combined with trastuzumab
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Sun Yat-sen University
Estrogen Receptor Positive Breast Cancer
A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers
Some breast cancers have estrogen receptors (ER+). The investigators know that some ER+ tumours can be cured by hormone therapy alone while other ER+ breast cancers cannot.
- Trial name
- PRESTO (NCT02238808)
- Testing
- Estradiol
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- AHS Cancer Control Alberta